FDA posted the letter on March 11, 2025. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1
What does the letter say, in brief?
| Company | USApeptide.com |
| Location | Not given in the letter |
| Website named | usapeptide.com |
| Letter dated | February 26, 2025 |
| Posted by FDA | March 11, 2025 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| FDA’s subject line | Unapproved New Drugs/Misbranded |
| Drugs named | semaglutide and tirzepatide |
| Kind of letter | Other |
| Reply asked within | 15 working days |
| Close-out letter | None posted as of November 20, 2026 |
| FDA record | MARCS-CMS 696885 |
What did FDA quote?
The letter quotes 12 passages. FDA quotes them as examples and says in most letters that the list is not exhaustive.1
not for human consumption,
not intended to diagnose, cure, mitigate, treat or prevent disease,
Semaglutide, also marketed under the brand names Ozempic, Rybelsus and Wegovy, is an FDA-approved injectable for weight loss…
Semaglutide is a potent once-weekly GLP-1 RA, significantly reducing HbA1c, body weight and systolic blood pressure.
… recently approved in the US to help type 2 diabetes patients better manage blood sugar.
Tirzepatide is a compound that has been shown to help with weight loss…
… stimulates the release of hormones that signal the brain to reduce food intake and increase feelings of fullness.
Semaglutide (GLP-1 Analogue) 5mg
4 more quotes are in the full letter below.
Which parts of the law did FDA cite?
The letter cites 4 sections of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.
| Section | What it says | Letters citing it |
|---|---|---|
| 502(f)(1) | A drug is misbranded if its labeling lacks adequate directions for use | 33 |
| 505(a) | A new drug may not be sold across state lines without an approved application | 48 |
| 301(a) | It is prohibited to introduce an adulterated or misbranded drug into interstate commerce | 142 |
| 301(d) | It is prohibited to introduce a drug into interstate commerce in violation of section 505 | 48 |
What did FDA ask the company to do?
In the letter’s own words:
Please notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence.
If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections.
FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1
Has FDA warned the seller I use?
Type a seller’s name or website. The search runs over all 164 letters in this database.
How many GLP-1 letters has FDA sent?
16 letters in this database are of the same kind as this one, other matters, such as a clinical investigator or a supplement. 151 of the 164 letters name semaglutide. 115 of the 164 letters name tirzepatide. The chart counts letters by the quarter of their date; the quarter of this letter is marked.
Which other sellers got a similar letter?
What does an FDA warning letter mean for someone buying from this seller?
FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.
FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.
A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.
What is the full text of the letter?
This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1
Read the full letter (1781 words)
This is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.usapeptide.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(a), 331(d), 331(k), 353(b), and 355(a)].
As discussed below, FDA has observed that www.usapeptide.com introduces into interstate commerce unapproved and misbranded semaglutide and tirzepatide drug products. There are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.usapeptide.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to protect the public from harm.
Unapproved New Drugs:
Despite statements on your product labeling and website such as “research use only,” “not for human consumption,” “lab purposes only,” and “not intended to diagnose, cure, mitigate, treat or prevent disease,” evidence obtained from your website establishes that certain products offered for sale by www.usapeptide.com are drugs intended for human use.
Examples of claims from the products’ labeling, including on your website listed above, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs for human use includes the following:
Semaglutide (GLP-1 Analogue) 5mg and Semaglutide (GLP-1 Analogue) 10mg:
“Semaglutide, also marketed under the brand names Ozempic, Rybelsus and Wegovy, is an FDA-approved injectable for weight loss…”
“Semaglutide is a potent once-weekly GLP-1 RA, significantly reducing HbA1c, body weight and systolic blood pressure.”
5mg Tirzepatide (Mounjaro) 5mg and 10mg Tirzepatide (Mounjaro) 10mg:
“… recently approved in the US to help type 2 diabetes patients better manage blood sugar.”
“Tirzepatide is a compound that has been shown to help with weight loss…”
“… stimulates the release of hormones that signal the brain to reduce food intake and increase feelings of fullness.”
These products are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act.
On www.usapeptide.com, you offer semaglutide marketed as “Semaglutide (GLP-1 Analogue) 5mg” and “Semaglutide (GLP-1 Analogue) 10mg.” While there are FDA-approved versions of semaglutide on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for the “Semaglutide (GLP-1 Analogue) 5mg” and “Semaglutide (GLP-1 Analogue) 10mg” offered by www.usapeptide.com. Currently there are three semaglutide products that are FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. FDA-approved semaglutide injection marketed under the brand name Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in individuals with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. FDA-approved semaglutide injection marketed under the brand name Wegovy is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in certain adult and pediatric patients. FDA-approved semaglutide tablets marketed under the brand name Rybelsus are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. FDA-approved semaglutide products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of thyroid C-cell tumors.
In addition, on www.usapeptide.com you offer tirzepatide marketed as “5mg Tirzepatide (Mounjaro) 5mg” and “10mg Tirzepatide (Mounjaro) 10mg.” While there are FDA-approved tirzepatide products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for the 5mg Tirzepatide (Mounjaro) 5mg” and “10mg Tirzepatide (Mounjaro) 10mg” offered by www.usapeptide.com. Currently there are two tirzepatide products that are FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. FDA-approved tirzepatide injection marketed under the brand name Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. FDA-approved tirzepatide injection marketed under the brand name Zepbound is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in certain adult patients. FDA-approved tirzepatide also bears a boxed warning addressing the risk of thyroid C-Cell tumors.
Misbranded Drugs:
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if its labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1) of the FD&C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner.
Because the aforementioned drugs are prescription drugs intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drugs fails to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. In addition, because the drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, www.usapeptide.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
Additionally, “Semaglutide (GLP-1 Analogue) 5mg,” “Semaglutide (GLP-1 Analogue) 10mg,” “5mg Tirzepatide (Mounjaro) 5mg,” and “10mg Tirzepatide (Mounjaro) 10mg” offered by www.usapeptide.com are intended for injection, which heightens the public health concern associated with these products and may further contribute to the potential for patient harm. On www.usapeptide.com you offer “Bacteriostatic Water 20ml Vial” and “10 PACK OF INSULIN SYRINGES ASST. SIZES.” Injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.
Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a healthcare practitioner licensed by law to administer prescription drugs. By offering the aforementioned drugs without requiring a prescription, www.usapeptide.com jeopardizes patient safety and misbrands the drugs under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].
FDA is sending this warning letter to www.usapeptide.com because of the inherent risks to consumers who purchase misbranded and unapproved new drugs. This letter is not intended to identify all the ways in which your products or operations might be in violation of the law. It is your responsibility to ensure that all products you offer for sale are in compliance with the FD&C Act and its implementing regulations. You should take prompt action to address any violations of the FD&C Act (which may include the offer for sale of similarly misbranded and/or unapproved new drugs other than the drugs noted above). We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a use for which they have not been approved by FDA and that you are not distributing misbranded products in violation of the FD&C Act.
Please notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction, without further notice. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days.
If you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the U.S.
Please direct your response and any inquiries to FDA at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
Sincerely,
/S/
S. Leigh Verbois, Ph.D.
Director, Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Content current as of:
03/11/2025
Regulated Product(s)
Drugs
Sources
- FDA. Warning letter to USApeptide.com, February 26, 2025 (MARCS-CMS 696885). fda.gov
- FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
- FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider